sertraline

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Obsessive Compulsive Disorder

Conditions

Obsessive Compulsive Disorder

Trial Timeline

Apr 4, 2012 → Sep 9, 2020

NCT ID

NCT01302080

About sertraline

sertraline is a pre-clinical stage product being developed by Pfizer for Obsessive Compulsive Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT01302080. Target conditions include Obsessive Compulsive Disorder.

What happened to similar drugs?

5 of 10 similar drugs in Obsessive Compulsive Disorder were approved

Approved (5) Terminated (1) Active (4)

✅DuloxetineEli LillyApproved

🔄Fluvoxamine maleate + PlaceboAbbViePhase 3

🔄quetiapine fumarate + SSRI/ClomipramineAstraZenecaPhase 3

✅Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)NovartisApproved

✅pregabalin + PlaceboPfizerApproved

✅EscitalopramLundbeckApproved

✅Escitalopram + Placebo oral tabletLundbeckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01302080	Pre-clinical	Completed	Apr 4, 2012	Sep 9, 2020	Obsessive Compulsive Disorder
NCT00585455	Pre-clinical	Terminated	Jan 1, 2006	Jul 1, 2009	Heart Failure
NCT00245557	Pre-clinical	Completed	Nov 1, 2004	Aug 1, 2008	Major Depressive Disorder
NCT02122393	Phase 3	Completed	Apr 1, 2002	Apr 1, 2005	Depression
NCT00118014	Approved	Completed	Jan 1, 2000	Aug 1, 2004	Impulse Control Disorders

Competing Products

17 competing products in Obsessive Compulsive Disorder

See all competitors

Product	Company	Stage	Hype Score
Duloxetine	Eli Lilly	Approved	43
Fluvoxamine maleate + Placebo	AbbVie	Phase 3	40
quetiapine fumarate + SSRI/Clomipramine	AstraZeneca	Phase 3	40
Quetiapine	AstraZeneca	Phase 2	35
Clomipramine (fluoxetine plus clomipramine) + Quetiapine (fluoxetine plus quetiapine) + Placebo (fluoxetine plus placebo)	Novartis	Approved	43
Bitopertin + Placebo + SSRI	Roche	Phase 2	35
pregabalin + Placebo	Pfizer	Approved	43
Sertraline + Levetiracetam + Placebo	UCB	Phase 2/3	30
Escitalopram	Lundbeck	Approved	36
Escitalopram + Placebo oral tablet	Lundbeck	Approved	44
Valbenazine + Placebo	Neurocrine Biosciences	Phase 2	39
RG1068 (Synthetic Human Secretin)	Repligen	Phase 2	32
Troriluzole + Placebo	Biohaven	Phase 3	34
Troriluzole + Placebo	Biohaven	Phase 3	34
Troriluzole + Placebo	Biohaven	Phase 2/3	32
Troriluzole (BHV-4157)	Biohaven	Phase 3	26
Nitrous Oxide + Nitrogen	Brain Biotech	Phase 2	32